Latest Articles

Publication Date
Leuprolide Acetate Market May See a Big Move | Major Giants- AbbVie, Mylan, Apotex - newstrail.com

Leuprolide Acetate Market May See a Big Move | Major Giants- AbbVie, Mylan, Apotex newstrail.com

Published: Sept. 13, 2025, 11:33 a.m.
Inguinal endometriosis: a rare entity of a common condition .

A woman in her mid-40s experienced a painful lump in the right groin area for 5 years, with exacerbation during menstruation, coughing and sneezing. Initial treatment with depot methylprednisolone acetate …

Published: Sept. 11, 2025, midnight
Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 as Demand for Hormone Therapy Accelerates – SNS Insider - SINA HONG KONG LIMITED

Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 as Demand for Hormone Therapy Accelerates – SNS Insider SINA HONG KONG LIMITED

Published: Sept. 2, 2025, 11:40 a.m.
Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 - GlobeNewswire

Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 GlobeNewswire

Published: Sept. 2, 2025, 10:32 a.m.
Gut Microbiota-Derived Acetate Ameliorates Endometriosis via JAK1/STAT3-Mediated M1 Macrophage Polarisation.

Endometriosis (EMs) is a common inflammatory disorder in women of reproductive age, severely impacting patients' quality of life and fertility. Current hormonal therapies offer limited efficacy, and surgical interventions often …

Published: Aug. 27, 2025, midnight
Factors Affecting Hormonal Therapy Ineffectiveness and Discontinuation due to Adverse Effects in Patients with Endometriosis-Associated Pain.

Endometriosis contributes to 5-21% of hospital admissions for pelvic pain. While hormonal therapies are pivotal in managing endometriosis-related pain, no single hormonal treatment suits all patients. We aimed to assess …

Published: Aug. 18, 2025, midnight
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... - Medical Dialogues

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... Medical Dialogues

Published: July 2, 2025, 11:31 a.m.
Key Trend In The Leuprolide Acetate Market In 2025: Innovative Drug Delivery Formulations Enhance Patient - EIN News

Key Trend In The Leuprolide Acetate Market In 2025: Innovative Drug Delivery Formulations Enhance Patient EIN News

Published: July 1, 2025, 11:02 a.m.
acetate on the uterine telocytes, - ResearchGate

acetate on the uterine telocytes, ResearchGate

Published: March 15, 2025, 6:16 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!